The World Health Organisation (WHO) has recommended Veklury (remdesivir) for the treatment of patients with non-severe COVID-19 who are at the highest risk of hospitalisation.
The revised recommendation was prompted by evidence from the phase 3 double-blind, placebo-controlled trial, PINETREE.
Data from the trial demonstrated that a three-day course of remdesivir treatment significantly reduced risk of hospitalisation or death – compared to the placebo – in non-hospitalised patients at high risk of disease progression…
